跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,070 条关于
“CDX0239-PBD”
全部
4,070
临床试验
3,240
药物
334
机构
19
资讯
477
去年
Novel ALK-Targeted Antibody-Drug Conjugate Demonstrates Complete Tumor Regression in Preclinical Cancer Models
去年
CStone Advances CS5001 ROR1-ADC to Phase Ib Trial for First-line DLBCL Treatment
去年
Daiichi Sankyo Presents Breakthrough ENHERTU Data at ASCO 2025 with Two Late-Breaking Phase 3 Trials
去年
ADC Therapeutics' Zynlonta Faces Competition, Poised for Potential Second-Line DLBCL Approval
2年前
Daiichi Sankyo's DS-9606 Shows Promise in Phase I Trial for Advanced Solid Tumors
去年
ADC Therapeutics Completes Enrollment in Phase 3 LOTIS-5 Trial for Zynlonta in Relapsed/Refractory DLBCL
2年前
Daiichi Sankyo's DS-9606 Shows Promise in Phase I Solid Tumor Trial
去年
Iksuda Therapeutics Initiates First-in-Human Trial of CD19-Targeted ADC IKS03 for Advanced B-Cell Non-Hodgkin Lymphoma
2年前
Daiichi Sankyo's DS-9606 Shows Early Promise in Advanced Solid Tumors Expressing CLDN6
11个月前
ADC Therapeutics Secures $60 Million to Advance ZYNLONTA Commercialization and Prepare for 2027 Relaunch
第 1 页,共 48 页
上一页
下一页